| Ident. | Authors (with country if any) | Title |
|---|
| 000237 (2011) |
C. Gibrat [Canada] ; F. Cicchetti [Canada] | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases : THE NEUROBIOLOGY OF NEURODEGENERATIVE DISORDER: FROM BASIC TO CLINICAL RESEARCH |
| 000253 (2011) |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
| 000268 (2011) |
Kaitlyn P. Roland [Canada] ; Jennifer M. Jakobi [Canada] ; Colin Powell [Canada] ; Gareth R. Jones [Canada] | Factors related to functional independence in females with Parkinson's disease: A systematic review |
| 000275 (2011) |
Lori-Ann R. Sacrey [Canada] ; Scott G. Travis [Canada] ; Ian Q. Whishaw [Canada] | Drug treatment and familiar music aids an attention shift from vision to somatosensation in Parkinson's disease on the reach-to-eat task |
| 000294 (2011) |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Ilona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Therese Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials |
| 000317 (2010) |
T. A. Zesiewicz [États-Unis] ; K. L. Sullivan [États-Unis] ; I. Arnulf [France] ; K. R. Chaudhuri [Royaume-Uni] ; J. C. Morgan [États-Unis] ; G. S. Gronseth [États-Unis] ; J. Miyasaki [Canada] ; D. J. Iverson [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology |
| 000340 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [États-Unis] | Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study |
| 000345 (2010) |
Rodger J. Elble [États-Unis] ; Oksana Suchowersky [Canada] ; Stephanie Shaftman [Canada, États-Unis] ; William J. Weiner [États-Unis] ; PENG HUANG [États-Unis] ; Barbara Tilley [États-Unis] | Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease |
| 000356 (2010) |
Janis M. Miyasaki [Canada] | Evidence-based initiation of dopaminergic therapy in Parkinson's disease |
| 000361 (2010) |
Bazoumana Ouattara [Canada] ; Fabrizio Gasparini [Suisse] ; Marc Morissette [Canada] ; Laurent Gregoire [Canada] ; Pershia Samadi [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Thérèse Di Paolo [Canada] | Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys |
| 000370 (2010) |
Edeltraut Kröger [Pays-Bas, Canada] ; Rob Van Marum [Pays-Bas] ; Patrick Souverein [Pays-Bas] ; Toine Egberts [Pays-Bas] | Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands: A Retrospective Cohort Study |
| 000378 (2010) |
Emmanuelle Pourcher [Canada, France] ; Sophie Remillard [Canada] ; Henri Cohen [Canada, France] | Compulsive habits in restless legs syndrome patients under dopaminergic treatment |
| 000379 (2010) |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew J. Lees [Royaume-Uni] | Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward |
| 000402 (2009) |
Anthony E. Lang [Canada] | When and how should treatment be started in Parkinson disease? |
| 000411 (2009) |
WEI SONG [Canada] ; Amar Patel [Canada] ; Hamid Y. Qureshi [Canada] ; DONG HAN [Canada] ; Hyman M. Schipper [Canada] ; Hemant K. Paudel [Canada] | The Parkinson disease-associated A30P mutation stabilizes α-synuclein against proteasomal degradation triggered by heme oxygenase-1 over-expression in human neuroblastoma cells |
| 000422 (2009) |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000448 (2009) |
Oliver Cooper [États-Unis] ; Arnar Astradsson [États-Unis] ; Penny Hallett [États-Unis] ; Harold Robertson [Canada] ; Ivar Mendez [Canada] ; Ole Isacson [États-Unis] | Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients |
| 000475 (2009) |
Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse] | Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease |
| 000481 (2009) |
Claire Gibrat [Canada] ; Martine Saint-Pierre [Canada] ; Mélanie Bousquet [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Francesca Cicchetti [Canada] | Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions |
| 000489 (2009) |
A. W. Zuardi [Brésil] ; J. A. S. Crippa [Brésil] ; J. E. C. Hallak [Brésil] ; J. P. Pinto [Brésil] ; M. H. N. Chagas [Brésil] ; G. G. R. Rodrigues [Brésil] ; S. M. Dursun [Canada] ; V. Tumas [Brésil] | Cannabidiol for the treatment of psychosis in Parkinson's disease |
| 000499 (2009) |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts |
